Monoclonal Antibodies for Migraine Prevention: Progress, but Not a Panacea

Migraine is a common chronic condition characterized by recurrent attacks of severe headache with associated symptoms such as light and sound sensitivity, nausea, vomiting, and focal neurological disturbances. In 2016, migraine affected an estimated 1.04 billion people worldwide. Migraine prevalence...

Full description

Saved in:
Bibliographic Details
Published inJAMA : the journal of the American Medical Association Vol. 319; no. 19; pp. 1985 - 1987
Main Authors Loder, Elizabeth W, Robbins, Matthew S
Format Journal Article
LanguageEnglish
Published United States American Medical Association 15.05.2018
Subjects
Disease prevention
Headache
Migraine
Monoclonal antibodies
Nausea
Neurological complications
Vomiting
Online AccessGet full text

Cover

More Information
Summary:Migraine is a common chronic condition characterized by recurrent attacks of severe headache with associated symptoms such as light and sound sensitivity, nausea, vomiting, and focal neurological disturbances. In 2016, migraine affected an estimated 1.04 billion people worldwide. Migraine prevalence and disease activity are highest among women during their childbearing years. Approximately 14% of people with migraine experience 5 or more attacks per month. For many patients, migraine episodes are debilitating, and overall, 25% of people with migraine report that they have missed a day of work or school because of migraine in the previous 3 months. Here, Loder and Robbins discuss Dodick et al's study evaluating the efficacy and tolerability of subcutaneous injections of fremanezumab for prevention of episodic migraine, defined as migraine occurring on fewer than 15 days per month.
Bibliography:SourceType-Scholarly Journals-1
content type line 14
ObjectType-Editorial-2
ObjectType-Commentary-1
content type line 23
ISSN:0098-7484
1538-3598
1538-3598
DOI:10.1001/jama.2018.4852